- Home
- PHIO vs AIMD Comparison
PHIO vs AIMD Comparison
Compare PHIO & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHIO | AIMD |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.6M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHIO | AIMD |
|---|---|---|
| Price | $1.19 | $1.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.67 | N/A |
| AVG Volume (30 Days) | ★ 7.1M | 56.4K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.43 |
| 52 Week High | $4.19 | $4.50 |
Technical Indicators
Market Signals| Indicator | PHIO | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 36.94 |
| Support Level | $1.03 | $1.26 |
| Resistance Level | $1.21 | $1.79 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.91 | 24.53 |
Price Performance
Historical ComparisonAbout PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.